Sequencing of BCMA-directed therapies for multiple myeloma

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myelomaПодробнее

BCMA-directed therapies for the treatment of relapsed/refractory multiple myelomaПодробнее

The optimal sequencing of CAR-T and other immunotherapies in multiple myelomaПодробнее

Feasibility of treatment with bispecifics in patients with myeloma with prior BCMA exposureПодробнее

Relapsed/Refractory Multiple Myeloma | Episode 3 | Med Table Talk™ Multiple Myeloma SeriesПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

How to best sequence bispecific antibodies and CAR-T therapy in multiple myelomaПодробнее

For a triple-class refractory patient entering 4L therapy, how to sequence BCMA/GPRC5D bispecifics?Подробнее

Unanswered questions regarding the sequencing of BCMA-targeting agents in multiple myelomaПодробнее

Continuing the Conversation: Exploring B-cell Maturation Antigen-Targeted Therapies and Managed CareПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myelomaПодробнее

CAR-T therapy in multiple myeloma: research blind spotsПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Sequencing BCMA-targeted therapies in myelomaПодробнее

Sequencing BCMA-targeted agents in multiple myelomaПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Moving BCMA-targeted agents to the frontline setting in myeloma & sequencing immunotherapiesПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее